



Code for the Assessment and Management of Conflict of Interest

Appendix A - Table 1:

Conflict of Interest: Special Considerations for Practice Guidelines Committee and Practice Metrics Committee Chairs, Committee Members and Writing Group Members Disclosures

Disclosures must be made at least annually and when material changes occur.

	Review By	Made Public
Chair and Members of the Practice Guidelines Committees	Ethics Committee	Yes
Chair and Members of the Practice Metrics Committee	Ethics Committee	Yes
Chair and Members of the CME Committee	Ethics Committee	Yes
Chair and Members of Writing Groups	Ethics Committee	At time of publication or release of Practice Guideline/Guidance or Quality Measures

Relationships with commercial entities whose interests may be impacted by guidelines or quality measures

Table 1 Activity	Chair & Chair-elect of Practice Guidelines Committee (PGC) and CME Committee	Chairs & Chair -elect of Practice Metric Committee & Chairs of Writing Groups	Members of Practice Guidelines Committee	Members of Practice Metric Committee *, CME Committee & Writing Groups
Leadership in Related Society: Board, Committee, Journal	Not permitted to serve as Editor or Associate Editor of competing journals (Section 1.G)	Permissible - Disclose and indicate if amount is less than \$10,000 annually for each relationship (Section 1.G)	Permissible - Disclose and indicate if amount is less than \$10,000 annually for each relationship (Section 1.G)	Permissible - Disclose and indicate if amount is less than \$10,000 annually for each relationship (Section 1.G)
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations	Disclose. Permissible only if uncompensated except for reasonable travel reimbursement. (Section 1.G)	Not permitted	Disclose and indicate if amount is less than \$10,000 per company per year and whether total compensation is less than \$50,000 per year. (Section 1.D)	Permitted for less than 50% of committee or writing group members who must disclose and indicate if amount is less than \$10,000 per company per year and whether total compensation is less than \$50,000 per year during the period of guidance or quality measures development. Note: Over 50% of committee or writing group members must be free of Direct Personal Financial Relationships with Companies. during the period of guidance or quality measures development (Section 3.C)

Table 1 Activity	Chair & Chair-elect of Practice Guidelines Committee (PGC) and CME Committee	Chair & Chair -elect of Practice Metric* Committee (PMC) & Chairs of Writing Groups	Members of Practice Guidelines Committee (PGC)	Members of Practice Metric Committee *, CME Committee & Writing Groups
Data Safety Monitoring Board for Industry or Commercial Enterprise	Disclose. Permissible only if uncompensated except for reasonable travel reimbursement (Section 1.G)	Not permitted. (EC-12-17-10-4)	Disclose and indicate if amount is less than \$10,000 per company per year and whether total compensation is less than \$50,000 per year. (Section 1.D)	Not permitted for Practice Metrics Committee members and writing group members. (EC-12-17-10-4) Permitted for less than 50% of CME committee members
Commercial Speakers' Bureau	Not permitted	Not permitted	Not permitted	Not permitted
Company Employee, Officer, Director (pharmaceutical, biotech, medical device, diagnostic and other therapeutic companies.)	Not permitted	Not permitted	Not permitted	No permitted
Stock/Stock Options with Relevant Pharmaceutical or Biotechnology Companies	Disclose. Not permitted, except in a diversified fund or are independently managed	Disclose. Not permitted, except in a diversified fund or are independently managed	Disclose and indicate if amount is less than \$10,000	Disclose. Not permitted, except in a diversified fund or are independently managed
Research Grants	Disclose [Funds must be paid to institution]	Disclose [Funds must be paid to institution]	Disclose [Funds must be paid to institution]	Disclose [Funds must be paid to institution]
Intellectual Property Rights (Patents, Royalties, Licensing fees)	Disclose. Not permitted for discoveries and patents that would be impacted by the guidelines under development	Disclose. Not permitted for discoveries and patents that would be impacted by the guidelines or measures under development	Disclose. Not permitted for discoveries and patents that would be impacted by the guidelines under development	Disclose. Not permitted for discoveries and patents that would be impacted by the guidelines under development
Consulting for equity (e.g., Venture Capital firm)	Not permitted	Not permitted	Not permitted	Not permitted
Expert Testimony	Disclose and indicate if amount is less than \$10,000 on an annual basis. Not permitted for companies that would be impacted by the work under development	Disclose and indicate if amount is less than \$10,000 on an annual basis. Not permitted for companies that would be impacted by the work under development	Disclose and indicate if amount is less than \$10,000 on an annual basis. Not permitted for companies that would be impacted by the work under development	Disclose and indicate if amount is less than \$10,000 on an annual basis. Not permitted for companies that would be impacted by the work under development

*The Practice Metrics Committee develops quality measures.